瑞康医药 (002589.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

3.6x

EV/EBITDA

23.5x

Market Cap

CNY 4.54B

MomentumView details →

1D Return

−5.03%

YTD Return

+0.00%

RSI (14)

51.2

ValuationView details →

P/E (Fwd)

3.6x

EV/EBITDA

23.5x

Market Cap

CNY 4.54B

RSI (14)

51.2

MomentumView details →

1D Return

−5.03%

YTD Return

+0.00%

ProfitabilityView details →

Gross Margin

10.36%

Net Margin

0.20%

EBITDA Margin

2.90%

ROE (TTM)

0.27%

ROA (TTM)

0.09%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

−5.94%

EPS YoY

+211.79%

FCF YoY

—

Revenue CAGR 3Y

−16.00%

EPS CAGR 3Y

−13.93%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.37

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.94x

Current Ratio

1.10x

Quick Ratio

1.03x

Div Yield

0.06%

Div Rate

CNY 0.00

Div Growth 1Y

−50.00%

Financials snapshotView financials →

Revenue (TTM)

7.25B

Net Income (TTM)

14.35M

Op. CF (TTM)

−27.00M

Latest newsMore news →

Ruikang Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 11.1353 million yuan, down 38.70% year-on-year.15d ago

Similar companies

博士眼镜300622.SZ 兰卫医学301060.SZ 漳州发展000753.SZ 华致酒行300755.SZ 辉隆股份002556.SZ 润贝航科001316.SZ Find similar companies →

Latest newsMore news →

Ruikang Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 11.1353 million yuan, down 38.70% year-on-year.15d ago